(Q48364637)

11 February 2018

title

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. (English)

1 reference

11 February 2018

main subject

phase III clinical trial

0 references

0 references

1 reference

12

Ludwig Kappos

1 reference

11 February 2018

3

Giancarlo Comi

1 reference

11 February 2018

Christian Confavreux

1

1 reference

11 February 2018

Paul O'Connor

2

1 reference

11 February 2018

Mark S Freedman

4

1 reference

11 February 2018

Aaron E Miller

5

1 reference

11 February 2018

Tomas P Olsson

6

1 reference

11 February 2018

Jerry S Wolinsky

7

1 reference

11 February 2018

Teresa Bagulho

8

1 reference

11 February 2018

Jean-Luc Delhay

9

1 reference

11 February 2018

Deborah Dukovic

10

1 reference

11 February 2018

Philippe Truffinet

11

1 reference

11 February 2018

TOWER Trial Group

13

1 reference

11 February 2018

publication date

23 January 2014

1 reference

11 February 2018

published in

Lancet Neurology

1 reference

11 February 2018

volume

13

1 reference

11 February 2018

issue

3

1 reference

11 February 2018

page(s)

247-256

1 reference

11 February 2018

Pathophysiology of multiple sclerosis and the place of teriflunomide

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

Placebo-controlled trial of oral laquinimod for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970308-9

7 January 2021

10.1016/S1474-4422(13)70308-9

Identifiers

DOI

1 reference

11 February 2018

PubMed ID

24461574

1 reference

11 February 2018